Latest Regulatory Filings News

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

The Supreme Court of Western Australia has approved the acquisition schemes allowing Li-FT Power to take full ownership of Winsome Resources, with trading suspension on the ASX set for 12 May 2026.

Aurizon reports volume growth across coal, bulk, and container freight for ten months to April, maintaining FY2026 EBITDA and dividend guidance amid a temporary $10 million fuel cost timing hit.

Noxopharm’s SOF-16 active ingredient demonstrated potent anti-inflammatory activity in patient-derived samples of systemic lupus erythematosus and rheumatoid arthritis, advancing its Sofra™ platform beyond topical applications.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.

Cleo Diagnostics has kicked off a staged manufacturing program with Bio-Techne to produce ovarian cancer test kits, moving from clinical sample collection to analytical validation and FDA submission preparation.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Multistack International is progressing with the sale of its core assets to Willing Y Limited, maintaining operations cautiously while cash reserves decline amid ongoing operating losses.

Nova Minerals has secured ASIC registration of its Scheme Booklet for re-domiciling to the US, alongside amendments to warrant terms that triple warrant exchange ratios ahead of the move.

Taiton Resources has completed a partial placement of 9.55 million shares to sophisticated investors, extending related option expiry dates to June 2029. A further tranche awaits due to delayed funds, while the company continues to advance exploration projects across South Australia and New South Wales.

Genesis Minerals is set to acquire Magnetic Resources for approximately A$639 million, offering Magnetic shareholders a 25-35% premium. The deal unlocks synergies at the Lady Julie Gold Project, where an updated underground production target extends mine life to 14-19 years with improved economics.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.